Anemocyte is excited to announce its participation in CPHI Japan 2025, taking place from April 9th to 11th at Tokyo Big Sight in Halls East 4, 5, and 6. The company will exhibit in the Italian Pavilion, organized by the ICE Agency, alongside 19 other Italian pharmaceutical companies.
CPHI Japan is a key event for the pharmaceutical industry in Asia, offering networking opportunities and insights into the latest trends. The 2025 edition will welcome over 730 exhibitors from more than 60 countries and feature 200+ educational sessions on industry advancements.
By participating, Anemocyte reaffirms its commitment to expanding in the Asian market and strengthening international collaborations in biotechnological therapies.
The company offers end-to-end solutions, from R&D to GMP manufacturing, specializing in:
The event’s seminars and workshops will explore the latest innovations, regulatory updates, and emerging trends in biopharmaceutical production. These sessions are a valuable resource for industry professionals looking to stay ahead and build strong connections.
CPHI Japan 2025 will provide Anemocyte with a platform to engage with suppliers, innovators, and industry leaders, paving the way for new partnerships and business opportunities. It is the perfect place to connect with the Japanese pharmaceutical ecosystem, establish strategic relationships, and explore local market prospects.
